Rockwell Medical Announces Four Triferic Posters Accepted for Presentation at American Society of Nephrology (ASN) Clinical Meeting November 2015

Rockwell Medical, Inc. RMTI, a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that four individual Triferic clinical abstracts were selected by ASN's Program Committee for poster presentation at the ASN Kidney Week 2015 Annual Meeting, November 3-8 at the San Diego Convention Center in San Diego, CA. Triferic is the only FDA approved iron product indicated to replace iron and maintain hemoglobin in hemodialysis patients in the United States. The following Triferic clinical presentations will be presented at ASN 2015: Triferic Maintains Hemoglobin and Iron Balance Long-Term: Phase III Extension Studies. (Oral Presentation) Triferic has a Safety Profile Similar to Placebo: An Integrated Safety Analysis of Phase 2 and Phase 3 Studies. (Poster) Structural Physical and Functional Characteristics of Triferic (ferric pyrophosphate citrate, FPC): A Novel Iron Compound for Pharmaceutical Applications. (Poster) Triferic does not Induce Non-Transferrin Bound Iron or Labile Plasma Iron: In-Vivo/In-Vitro Correlation. (Poster)